Research programme: disease-associated protein targets - CAT/Xerion
Alternative Names: Disease-associated protein targets research programme – CAT/XerionLatest Information Update: 08 May 2008
At a glance
- Originator Cambridge Antibody Technology; Xerion Pharmaceuticals
- Developer Xerion Pharmaceuticals
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 22 Jun 2006 No development reported - Preclinical for Undefined in Germany (unspecified route)
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
- 23 Sep 2003 Preclinical trials in Germany (unspecified route)